Skip to main
CRDL

Cardiol Therapeutics (CRDL) Stock Forecast & Price Target

Cardiol Therapeutics (CRDL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cardiol Therapeutics is poised for success due to the positive results of their CardiolRx program, with statistically significant improvement in left ventricular mass and a clean safety profile that reinforces its potential. Additionally, the failure of AstraZeneca's AZD3427 highlights the potential of Cardiol's alternative, non-vasodilatory approach to treating heart failure with their CRD-38 program, which has shown potential for improving LV mass and its underlying components. Coupled with promising preclinical studies and a strong valuation, Cardiol presents a lucrative investment opportunity.

Bears say

Cardiol Therapeutics is currently undervalued with a market capitalization of only $98M, as investors are not fully aware of the positive signals from the ARCHER and MAVERIC trials, which demonstrate the potential of their lead candidate CardiolRx in treating recurrent pericarditis and myocarditis. Furthermore, the ongoing development of CRD-38 offers additional potential and strengthens the company's portfolio.

Cardiol Therapeutics (CRDL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardiol Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardiol Therapeutics (CRDL) Forecast

Analysts have given Cardiol Therapeutics (CRDL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Cardiol Therapeutics (CRDL) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardiol Therapeutics (CRDL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.